Author(s):
Priyadharshini Ananthathandavan, Damodharan Narayanasamy
Email(s):
damodhan@srmist.edu.in
DOI:
10.52711/0974-360X.2025.00160 
Address:
Priyadharshini Ananthathandavan1, Damodharan Narayanasamy2*
1Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Chengalpattu District, Tamilnadu, India.
2Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Chengalpattu District, Tamilnadu, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2025
ABSTRACT:
CYP2C19 enzyme plays a crucial role in the metabolism of many drugs and PPIs are found to be potent inhibitors of CYP2C19, thereby affecting the clinical outcome of certain drugs that are administered concomitantly. Ilaprazole due to its pharmacokinetic variability may not have inhibitory effect on CYP450 isoforms. The current study aims to examine the inhibitory activity of ilaprazole to conventional PPIs using in-silico methodologies for cytochrome P450 3A4 and 2C19. We used Lipinski's rule of five to PPIs in this in-silico investigation, and we also assessed the ADMET characteristics of ligands. Additionally, docking studies were conducted for PPIs. Different targeted proteins were docked with each PPI (PDB IDs: 4D7D, 4GQS). Based on the docking findings, the current study found that ilaprazole inhibits the CYP3A4 and 2C19 enzymes, but to a lesser extent than other conventional PPIs. Proton pump inhibitors that show pharmacokinetic drug interactions mediated by these enzymes have poor therapeutic outcomes. In such cases, ilaprazole might be the suitable option among PPIs
Cite this article:
Priyadharshini Ananthathandavan, Damodharan Narayanasamy. In-silico Assessment of CYP2C19 and CYP3A4 Inhibitory Potential of Ilaprazole. Research Journal Pharmacy and Technology. 2025;18(3):1113-7. doi: 10.52711/0974-360X.2025.00160
Cite(Electronic):
Priyadharshini Ananthathandavan, Damodharan Narayanasamy. In-silico Assessment of CYP2C19 and CYP3A4 Inhibitory Potential of Ilaprazole. Research Journal Pharmacy and Technology. 2025;18(3):1113-7. doi: 10.52711/0974-360X.2025.00160 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-3-21
6. REFERENCES:
1. Cho H, Choi MK, Cho DY, et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol. 2012; 52(7): 976-984. doi:10.1177/0091270011408611
2. Rahman Abdul Mohd, D Ramakrishna, Shashidhar Purra, Mehnoor Farheen, Faheemuddin Mohammed. Study of effect of Proton Pump Inhibitors on Blood Constituents in Albino Wistar Rats. Research Journal of Pharmacology and Pharmacodynamics. 2021; 13(2): 43-5. DOI: 10.52711/2321-5836.2021.00009
3. Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012; 42(3): 278-284. doi:10.3109/00498254.2011.622416
4. Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research J. Pharm. and Tech. 2012; 5(1): Jan. 20-26.
5. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018; 14(4): 447-460. doi:10.1080/17425255.2018.1461835
6. Niu M, Zhou Y, Xie Y, et al. Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori. Front Pharmacol. 2022; 13: 771876. Published 2022 Apr 27. doi:10.3389/fphar.2022.771876
7. Sri Roja. I, E. Shanmugapriya, P. Shanmugasundaram. Comparative Study of efficacy of Ilaprazole and Omeprazole in Patients with Acid Peptic Disease. Research J. Pharm. and Tech. 2017; 10(7): 2205-2209. DOI: 10.5958/0974-360X.2017.00389.4
8. Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012; 43(3): 212-224. doi:10.1016/j.arcmed.2012.04.004
9. Misam Polara, Dipil Patel, Musharraf Chauhan, Svapnil Sanghavi, Manish Patel, Jayvadan Patel. Delayed Release Formulations of Proton Pump Inhibitors-Similarities and Differences - A Review. Research J. Pharm. and Tech. 2012; 5(4): April 462-465.
10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3): 3-26. doi:10.1016/s0169-409x(00)00129-0
11. Lagorce D, Douguet D, Miteva MA, Villoutreix BO. Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Sci Rep. 2017; 7: 46277. Published 2017 Apr 11. doi:10.1038/srep46277
12. Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9): 4066-4072. doi:10.1021/acs.jmedchem.5b00104
13. Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022; 50(W1): W159-W164. doi:10.1093/nar/gkac394
14. Vipul Kumar, Sudhakar Kancharla, Manoj Kumar Jena. In silico screening of FDA approved drugs predicts the therapeutic potentials of Antibiotic drugs against the papain like protease of SARS-CoV-2. Research Journal of Pharmacy and Technology. 2021; 14(8):4035-9. DOI: 10.52711/0974-360X.2021.00699
15. Sakshi Nand, Neelabh. Therapeutic effect of certain Indian medicinal compounds against the Corona Virus: An in-silico study. Asian Journal of Pharmaceutical Research. 2021; 11(3): 167-2. DOI:10.52711/2231-5691.2021.00031
16. Vaithiyalingam M, Mohan Kumar R, Khagar P, Sabarathinam S, Alghazwani Y, Chidambaram K. Isolation of 6-gingerol and semi-synthesis of 1,4-benzodiazepines derivatives: An in-situ pharmacokinetics properties, molecular docking and molecular dynamics simulation assessments. Saudi J Biol Sci. 2024; 31(8): 104048. doi:10.1016/j.sjbs.2024.104048
17. Vaithiyalingam, M., Sumathi, D.L. and Sabarathinam, S. Isolation and In silico Study of Curcumin from Curcuma longa and Its Anti-Diabetic Activity. Appl Biochem Biotechnol 195, 947–957 (2023). https://doi.org/10.1007/s12010-022-04173-3
18. Vaithiyalingam M, Sumathi DL, Sabarathinam S. Isolation and In silico Study of Curcumin from Curcuma longa and Its Anti-Diabetic Activity. Appl Biochem Biotechnol. 2023; 195(2): 947-957. doi:10.1007/s12010-022-04173-3
19. Viral Patel. Design, Development, Evaluation and Optimization of Antiulcer Delayed Release Tablets. Research J. Pharm. and Tech 6(6): June 2013; Page 669-684.
20. Raghu Khimani, Pankaj Kapupara. Development and Validation of HPLC Method for determination of Ilaprazole and Levosulpride. Research J. Pharm. and Tech. 2018; 11(4): 1491-1495. DOI: 10.5958/0974-360X.2018.00277.9
21. Neethu Sara George, Sujatha Palatheeya, Ramakrishna Prudhivi, Anjali Maria Mathew. Evaluation of Appropriateness of Intravenous Pantoprazole in Inpatients of Tertiary Care Hospital. Research J. Pharm. and Tech. 2021; 14(3): 1441-1446. DOI: 10.5958/0974-360X.2021.00257.2
22. Pradeepa BR, Vijayakumar TM, Dhivya LS, Manikandan K. In-silico comparison of cytochrome P450 inhibitory and dopaminergic activity of Piperine, Curcumin and Capsaicin. Nat Prod Res. 2023; 37(17): 2888-2893. doi:10.1080/14786419.2022.2134862
23. Pankaj Rakha, Raj Kumar, Supriya, Nidhi, Manju Nagpal , Gitika Arora. Gastroesophageal Reflux Disease: Pathophysiology and Treatments Available. Research J. Pharmacology and Pharmacodynamics. 2010; 2(2): 160-164.
24. Ananthathandavan P, Narayanasamy D. Computational drug-drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel. Future Sci OA. 2024; 10(1): FSO966. Published 2024; May 20. doi:10.2144/fsoa-2023-0277